KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.
KAIST spin-off with acute-kidney-injury drug BX-001N past phase 1 and in phase 2a: a clinical-stage therapeutic at Series A, the Pulse sweet spot.
Evidence from the records
- “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea”
- “Series A”
- Intro path
- Co-investors include Solbrain Holdings and WeVentures.
- First step
- Send BILIX's phase 1 data package to the Pulse team.